OCT Agreement and Precision Study

Completed

• Conditions: Normal Eyes; Eyes With Glaucoma; Eyes With Retinal Disease

• Registration Number: NCT02045823
• Lead Sponsor: Topcon Medical Systems, Inc.

Brief Summary

To demonstrate clinical substantial equivalence of 3D OCT-1 Maestro as comparable to the commercially available iVue and NW-300. Also, to demonstrate clinical substantial equivalence of 3D OCT-2000 Maestro as comparable to the commercially available NW-300.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-01
• Study First Submitted: 2014-01-22
• Study First Submitted QC: 2014-01-22
• Study First Posted: 2014-01-27
• Primary Completion: 2014-03
• Study Completion: 2014-03
• Status Verified: 2022-06
• Last Update Submitted: 2022-06-06
• Last Update Posted: 2022-06-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Retinal Thickness	Day 1

Trial Locations

Locations (1)

New York VA; 🇺🇸 Jamaica, New York, United States